Intensification regimen 2 for advanced head and neck squamous cell carcinomas

Archives of Otolaryngology - Head and Neck Surgery

Volumn 125, Issue 12, 1999, Pages 1313-1318

  Grecula, John C ^a   Schuller, David E ^a   Rhoades, Chris A ^a   Au, Jessie L S ^a   Nag, Subir ^a   Bauer, Constance J ^a   Agrawal, Amit ^a   Martinez Monge, Rafael ^a   Johnson, Andrew ^a   Young, Donn ^a   Gahbauer, Reinhard A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD CANCER; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; NECK CANCER; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; XEROSTOMIA;

EID: 0032765055     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.125.12.1313     Document Type: Article

References (24)

1. Landis S, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:12-13.
2. Kramer S, Gelber RD, Snow JB, et al. Combined radiation and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 1987;10:19-30.
3. Fu K. Combined-modality therapy for head and neck cancer. Oncology. 1997; 11:1781-1796.
4. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol. 1998;16:1310-1317.
5. Al-Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys. 1997;37:777-782.
6. Bachaud JM, Cohen-Jonathan E, Alzien C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36: 999-1004.
7. Laramore GE, Scott CB, Al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23:705-713.
8. Schuller D, Grecula J, Gahbauer R, et al. Intensified regimen for advanced head and neck squamous cell carcinomas. Arch Otolaryngol Head Neck Surg. 1997; 123:139-144.
9. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiology Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
10. Green S, Weiss GR. Southwest Oncology Group standard response criteria, end-point definitions, and toxicity criteria. Invest New Drugs. 1992;10:239-253.
11. Au JL, Li D, Gan Y, et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res. 1998;59:2141-2148.
12. Gan Y, Wientjes MG, Au JL. Relationship between paclitaxel activity and pathobiology of human solid tumors. Clin Cancer Res. 1998;4:2949-2955.
13. Johnson AL, Johnston JS, Grecula JC, Schuller DE, Au JL. Additive cytotoxicity of Taxol and radiation in human head and neck cancer cells. In: Proceedings of the 87th Annual Meeting of the American Association for Cancer Research; April 20-24, 1996; Washington, DC. Page 609. Abstract.
14. Johnson AL, Schuller DE, Johnston JS, Grecula JC, Au JL-S. Interaction of Taxol, radiation, and cisplatin in human head and neck cancer cells. Paper presented at: International Conference on Head and Neck Cancer; July 28-August 11, 1996; Toronto, Ontario. Abstract.
15. Gan Y, Wientjes G, Schuller D, Au J. Pharmacodynamics of Taxol in human head and neck tumors. Cancer Res. 1996;56:2086-2093.
16. Smith R, Thornton D, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol. 1995;22(suppl):41-46.
17. Forastiere AA, Neuberg D, Taylor SG, et al. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. Monogr Natl Cancer Inst. 1993;15:181-184.
18. Forastiere AA, Urba S. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol. 1995;22(suppl):24-27.
19. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991;9:1692-1703.
20. Rowinsky EK, Chaudhry V, Forastiere AA, et al. A phase I and pharmacokinetic study of paclitaxel and cisplatin with granulocyte colony stimulating factor. J Clin Oncol. 1993;11:2010-2020.
21. Steinberg L, Hassan M, Olmsted L, et al. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Semin Oncol. 1997;24(suppl 19):S19-51-S19-56.
22. Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, Kyprianou K, Kolitsi G, Dardoufas K. A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during x-radiation therapy: a preliminary report. Int J Radiat Oncol Biol Phys. 1998;42: 551-556.
23. Symonds RP. Treatment-induced mucositis: an old problem with new remedies. Br J Cancer. 1998;77:1689-1695.
24. Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical oral G-CSF on oral mucositis: a randomized placebo-controlled trial. Bone Marrow Transplant. 1998; 22:781-785.